AIBODY Partners with German Heart Centre Berlin to Revolutionize Diagnosis and Treatment of Congenital Heart Disease

LONDON–(BUSINESS WIRE)–AIBODY, the world’s first Physiology-as-a-Service platform, announced today that it has signed a collaboration agreement with the German Heart Centre Berlin (DHZB), a leading medical research institute specializing in cardiovascular disease. This agreement focuses on the development of a suite of innovative solutions that will facilitate the diagnosis and treatment of congenital heart disease. … [Read more…]

European Commission Approves IMBRUVICA® (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Approval marks the first all-oral, once-daily, fixed-duration Bruton’s tyrosine kinase (BTK) inhibitor-based regimen for first-line treatment of CLL BEERSE, Belgium–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission granted marketing authorisation for the expanded use of IMBRUVICA® (ibrutinib) in an all-oral, fixed-duration (FD) treatment combination with venetoclax (I+V) for … [Read more…]

GenomOncology and Congenica Announce Collaborative Development of Novel Precision Oncology Solution

CAMBRIDGE, England–(BUSINESS WIRE)–#lifechanginganswers–Congenica, a UK-based digital health company that enables the rapid analysis and interpretation of genomic data, has selected the GenomOncology Precision Oncology Platform for the development of a novel ground-breaking CE-IVD Precision Oncology Solution. Driven by the increasing adoption of cancer genomics and the growing need to individualize therapeutic recommendations, Congenica is developing … [Read more…]

PureTech Health: Notice of Half-Yearly Results

BOSTON–(BUSINESS WIRE)–PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) plans to announce its half-yearly results for the six months ended June 30, 2022, on Thursday, August 25, 2022. A presentation and conference call for analysts and shareholders will take place at 9:00am EDT / 2:00pm BST on the day of publication, and … [Read more…]

Revolutionizing Healthcare Testing: 1health Unveils Next Generation Diagnostic Platform that Enables Precision Medicine at Scale

Labs can now launch next-gen testing in days versus months and improve patient experience and outcomes SAN FRANCISCO–(BUSINESS WIRE)–1health.io Inc. (“1health”), an industry-leading healthcare tech company that empowers laboratories to make diagnostic testing accessible and affordable at scale, announces the launch of its Next Generation Diagnostic Platform. With 1health’s innovative platform, laboratories can expand market … [Read more…]

DIC: Suizenji Nori Blue-Green Algae New Key Indoor Cultivation Tech Unlocks Stable, Scalable Algaculture for Delivering SACRANTM Moisture-Retention Effect for More Ethical and More Sustainable Cosmetics and Skincare Products

DIC leverages world-class algae cultivation tech, expanding health, personal care offerings TOKYO–(BUSINESS WIRE)–#Biotech—DIC Corporation (TOKYO:4631) and biotech startup Green Science Materials, Inc. (GSM) expand their collaboration on Suizenji Nori blue-green algae and SACRANTM polysaccharide extract, developing Suizenji Nori indoor mass cultivation technology needed to deliver the stable production of SACRANTM required for global scale. This … [Read more…]

Signify Health Announces Second Quarter 2022 Results

Financial Highlights Second Quarter 2022: Revenue of $246.2 million, an increase of 16% from second quarter 2021 GAAP net loss of $490.0 million, which includes a $519.9 million loss on impairment related to our decision to exit the Episodes of Care Services segment. Non-GAAP adjusted EBITDA1 of $62.6 million, an increase of 15% from second … [Read more…]

Geron to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference

FOSTER CITY, Calif.–(BUSINESS WIRE)–Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, plans to participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 10, 2022 … [Read more…]

Bruker Reports Second Quarter 2022 Financial Results

Q2 2022 reported revenue growth of 3.1% year-over-year (yoy); organic revenue growth of 8.8% Q2 2022 GAAP EPS $0.33; non-GAAP EPS $0.45, up 2.3% yoy Maintaining FY 2022 guidance for high, single-digit organic revenue growth, non-GAAP operating profit margin expansion and non-GAAP EPS increase BILLERICA, Mass.–(BUSINESS WIRE)–$BRKR #BRKR—Bruker Corporation (Nasdaq: BRKR) today announced financial results … [Read more…]